Mutual of America Capital Management LLC Purchases Shares of 2,897 iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Mutual of America Capital Management LLC purchased a new stake in iTeos Therapeutics, Inc. (NASDAQ:ITOSGet Rating) in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 2,897 shares of the company’s stock, valued at approximately $93,000.

Other hedge funds also recently bought and sold shares of the company. Point72 Asset Management L.P. purchased a new stake in iTeos Therapeutics during the fourth quarter valued at about $4,890,000. Comerica Bank purchased a new stake in iTeos Therapeutics during the first quarter valued at about $523,000. New York State Teachers Retirement System purchased a new stake in iTeos Therapeutics during the first quarter valued at about $196,000. Fifth Lane Capital LP purchased a new stake in iTeos Therapeutics during the fourth quarter valued at about $678,000. Finally, Walleye Capital LLC purchased a new stake in iTeos Therapeutics during the fourth quarter valued at about $1,595,000. 94.71% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, Director Aaron I. Davis sold 338,000 shares of the stock in a transaction that occurred on Wednesday, May 11th. The stock was sold at an average price of $18.25, for a total value of $6,168,500.00. Following the transaction, the director now owns 2,154,058 shares in the company, valued at $39,311,558.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In related news, Director Aaron I. Davis sold 225,000 shares of the stock in a transaction that occurred on Monday, May 9th. The stock was sold at an average price of $23.40, for a total value of $5,265,000.00. Following the transaction, the director now owns 2,592,058 shares in the company, valued at $60,654,157.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Aaron I. Davis sold 338,000 shares of the stock in a transaction that occurred on Wednesday, May 11th. The shares were sold at an average price of $18.25, for a total value of $6,168,500.00. Following the transaction, the director now owns 2,154,058 shares in the company, valued at approximately $39,311,558.50. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 564,171 shares of company stock worth $11,456,346. Insiders own 3.95% of the company’s stock.

iTeos Therapeutics Price Performance

Shares of ITOS opened at $25.14 on Wednesday. The company has a market capitalization of $893.48 million, a price-to-earnings ratio of 3.22 and a beta of 1.50. iTeos Therapeutics, Inc. has a fifty-two week low of $16.21 and a fifty-two week high of $52.43. The business’s 50-day moving average is $21.33 and its 200-day moving average is $28.24.

iTeos Therapeutics (NASDAQ:ITOSGet Rating) last issued its earnings results on Thursday, May 12th. The company reported $1.82 earnings per share for the quarter, beating analysts’ consensus estimates of $0.80 by $1.02. The business had revenue of $152.52 million during the quarter, compared to analyst estimates of $63.30 million. Equities research analysts expect that iTeos Therapeutics, Inc. will post 4.38 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Piper Sandler reduced their price objective on shares of iTeos Therapeutics from $42.00 to $34.00 in a research note on Wednesday, May 11th.

iTeos Therapeutics Profile

(Get Rating)

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.

Featured Articles

Want to see what other hedge funds are holding ITOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iTeos Therapeutics, Inc. (NASDAQ:ITOSGet Rating).

Institutional Ownership by Quarter for iTeos Therapeutics (NASDAQ:ITOS)

Want More Great Investing Ideas?

Receive News & Ratings for iTeos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iTeos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.